Novavax, Inc. · NASDAQ:NVAX
Novavax — International Society of Vaccines 2014
27 slides from Novavax's conference presentation, Oct 26, 2014
Slide 1: RSV F Nanoparticle Vaccine: Update
RSV F Nanoparticle Vaccine: Update Gregory M. Glenn M.D., SVP R&D Summary of Findings in Recent Clinical Trials International Society of Vaccines October 26, 2014 1 www.novavax.com
Slide 2: The Problem with RSV The RSV F Nanoparticle Vaccine Summary of Immunogenicity to date
• The Problem with RSV • The RSV F Nanoparticle Vaccine • Summary of Immunogenicity to date • Supportive Preclinical Studies • Summary of Clinical Results in Women of Childbearing Age • M202: Women of Childbearing Age Results and dose selection • M203: Safety and immunogenicity in 3rd trimester wome
Slide 3: Target Populations for an RSV Vaccine
Target Populations for an RSV Vaccine Young Infants Pediatric Elderly via Maternal Immunization Provide protection for Decrease respiratory Mitigate RSV disease infants younger than six disease burden in burden that results from months and most at risk children, prevent medical waning immunity and o
Slide 4: Naturally Derived Immunity is Robust but Relatively Ineffective: A Persistent Puzzle
Naturally Derived Immunity is Robust but Relatively Ineffective: A Persistent Puzzle The Very Young Receive the Mother’s RSV Antibodies Transplacentally but the Decades of Mother’s RSV Exposure Does not Evoke an Immune Response That is Highly Protective Antibody Transfer Age of Hospitalization Peak
Slide 5: RSV F Nanoparticle Antigen Vaccine Technology
RSV F Nanoparticle Antigen Vaccine Technology RSV F Recombinant Protein Nanoparticles Near Full Length, Recombinant RSV F Fusion (F) RSV virus McLellan JS RSV F trimer • Purified, recombinant near-full-length RSV F fusion glycoprotein trimers • Trimers spontaneously assemble into 40-60 nm nanopartic
Slide 6: RSV F: Genetic Stability of Surface Glycoproteins is Critical in Selection of the Vaccine Target
RSV F: Genetic Stability of Surface Glycoproteins is Critical in Selection of the Vaccine Target RSV Surface Glycoproteins • Attachment Protein (G) • Fusion Protein (F) Strain changes due to the G protein variability Frequency of Amino Acid Changes In Glycoproteins G and F The Fusion F protein chang
Slide 7: F Protein Nanoparticle Vaccine Displays Site II: Palivizumab Binding
F Protein Nanoparticle Vaccine Displays Site II: Palivizumab Binding • Palivzimab binds avidly to the F protein nanoparticle vaccine 120 Competitive Inhibition (%) 100 80 50% Inhibition = 2.1 µg/ml 60 40 20 0 25 µg 2.5 µg 0.25 µg 0.125 µg Palivizumab (µg/ml) binding RSV F Antigenic site II: Amino ac
Slide 8: Palivizumab-Competitive ELISA (PCA)
Palivizumab-Competitive ELISA (PCA) Labeled Palivizumab Human Immune Sera Vaccine-induced antibodies compete with palivizumab for binding to Site II on the F Protein Protective levels elucidated by the cotton rat studies: 30ug/ml 8
Slide 9: Vaccine Immunity: Amplifying the Near Absence of Palivizumab Competing Antibodies
Vaccine Immunity: Amplifying the Near Absence of Palivizumab Competing Antibodies • PCA levels up to 400μg/ml, potential for placental concentration effect • Palivizumab ‘protective’ at 30μg/ml in CR • PCA “Near absence” suggests that the site is immunologically cryptic, important to reinfection 500
Slide 10: Outcomes of the RSV F Nanoparticle Vaccine Development Program to Date
Outcomes of the RSV F Nanoparticle Vaccine Development Program to Date • In preclinical models,the vaccine is protective Concordance Between Increased Anti-F both with active and passive studies, as well and PCA After Vaccination as maternal immunization • The vaccine is well tolerated and immunogen
Slide 11: Summary of Clinical Studies to Date
Summary of Clinical Studies to Date • Study 101: Safety and immunogenicity in healthy adults (n=120) ‒ Stimulated robust immune responses ‒ Induced production of palivizumab-competing antibodies • Study E101: Safety and Imunogenicity and dose finding in Elderly Adults ‒ Safety, dose selection • Stud
Slide 12: Maternal Antibody Transfer
Maternal Antibody Transfer Active transport of mother’s antibodies into baby’s blood • Mother’s antibodies from past infections and vaccines • At full term baby has >100% of mother’s antibody levels. Antibodies from natural RSV infection of Antibody mothers over decades are actively Mother’s Blood t
Slide 13: Modeling Maternal Antibody Transport in the Guinea Pig
Modeling Maternal Antibody Transport in the Guinea Pig Transfer of Vaccine Guinea Pigs Antibodies in Humans Guinea pig transfer rates of anti-F IgG and two other functional measures appear similar to licensed protein vaccines 13
Slide 14: Maternal Immunization Prevents Tachypnea in Infant Baboons Challenged with RSV
Maternal Immunization Prevents Tachypnea in Infant Baboons Challenged with RSV Fold Rise in Respiratory Rate Above Baseline In Placebo and Transplacentally Immunized Infant Baboons Maternal immunization study* p=0.0001 • Pregnant Baboons immunized Fold Rise, Respiratory Rate in 3rd trimester • Devel
Slide 15: M202 Clinical Trial: Safety and Immunogenicity in Women of Child-Bearing Age
M202 Clinical Trial Safety and Immunogenicity in Women of Child-Bearing Age Trial Design • 720 healthy women, 18-35 years • Placebo-controlled, dose-ranging trial to assess safety and the kinetics and magnitude of the anti-RSV immune response • 60 or 120µg RSV F vaccines adsorbed with descending dos
Slide 16: Women of Childbearing Age Immunogenicity: One Dose vs Two Dose Regimens
Women of Childbearing Age Immunogenicity: One Dose (120ug) vs Two Dose (60ug) Regimens, and Alum Titration (M202) • Primary endpoint-Anti F IgG response • Single dose, 120µg F with 0.4mg Al, provides the best immune response to D56 • Single dose improves compliance in maternal immunization • Paliviz
Slide 17: Microneutralization: Responses to 1-dose Regimens (M202)
Microneutralization: Responses to 1-dose Regimens (M202) • Groups E, F, and G = 120µg F + 0.8, 0.4, or 02 mg Al x 1 dose, respectively • Major RSV/A MN response at Day 28 in 1-dose groups • Little impact of formulation • Minimal decrement through Day 56 17
Slide 18: M202 Women of Childbearing Age: Palivizumab Competing Antibodies
M202 Women of Childbearing Age:Palivizumab Competing Antibodies • PCA levels up to 400μg/ml, potential for placental concentration effect • Palivizumab ‘protective’ at 30μg/ml in CR 500 Two-dose, 60μg One-dose, 120μg Selected regimen Palivizumab-Competitive ELISA 400 300 Responses Day 0 Day 14 200 D
Slide 19: PCA Responses in Women of Childbearing Age: Coverage of Infants by Gestational Age
PCA Responses in Women of Childbearing Age: Implications for Coverage of Infants Born at Different Gestational Ages CDC Birth Frequencies by Gestational Week Data 1,600 1,400 1,200 U.S. Births (in thousands) 1,000 800 600 400 > 90% of Births 200 0 35 36 37 38 39 40 41 42 43 Weeks All Births * PCA =
Slide 20: PCA Responses in Women of Childbearing Age: Coverage of Infants by Gestational Age
PCA Responses in Women of Childbearing Age: Implications for Coverage of Infants Born at Different Gestational Ages CDC Birth Frequencies by Gestational Week Data 1,600 1,400 1,200 U.S. Births (in thousands) 1,000 800 600 Peak Transplacental Antibody Transfer 400 > 90% of Births 200 0 35 36 37 38 39
Slide 21: PCA Responses in Women of Childbearing Age: Coverage of Infants by Gestational Age
PCA Responses in Women of Childbearing Age: Implications for Coverage of Infants Born at Different Gestational Ages PCA* Kinetic Curve for Single Dose (120µg RSV-F + 0.4 mg Al) Aligned Over CDC Birth Frequencies by Gestational Week Data 1,600 450 1,400 400 350 1,200 U.S. Births (in thousands) 300 1,
Slide 22: Modeling Effect of PCA via Maternal Immunization: Potential Clinical Benefit for Infants
Modeling Effect of PCA via Maternal Immunization: Potential for Clinical Benefit for infants up to 5-6 months “Protection”* * Protective level for palivizumab at 30 µg/mL 22
Slide 23: M203: RSV F Nanoparticle Vaccine Candidate, First Study in Pregnant Women
M203: RSV F Protein Nanoparticle Vaccine Candidate, First Study in Pregnant Women • Trial synopsis ‒ Randomized, observer-blinded, placebo-controlled ‒ 25 active, 25 placebo third trimester women ‒ Active will receive 120ug RSV F/ 0.4 mg Aluminum Phosphate ‒ Immunization at 33-35 gestational age ‒ M
Slide 24: Rate of RSV Infections Decreased by 50% in RSV F Vaccinees
Rate of RSV Infections Decreased by 50% in RSV F Vaccinees Western Blot Analysis • Immunized at the beginning of RSV season • Immunization complete by day 56 • Assessed for new onset infections between day 56 and 112 by Western Blot • Evidence of recent past infection balanced between placebo and va
Slide 25: Implications of Decreased Rate of RSV Infections
Implications of Decreased Rate of RSV Infections • Healthy adults have clinically significant RSV disease (O’ Shea et al, JID) • Pregnant women who contract influenza have more adverse outcomes and increased fetal loss • Vaccine Efficacy is generally better the more severe the case definition • RSV
Slide 26: Conclusions
Conclusions • RSV causes severe and recurrent infections in the face of robust natural immunity • Natural immunity induces little Site II immunity ‒ Immunological cryptic and critical to protection? • The RSV F nanoparticle vaccine induces Site II immunity and neutralizing antibodies ‒ These antibod
Slide 27: Acknowledgements
Acknowledgements Discovery Gale Smith, Mike Massare, Ye Liu, David Flyer, Yingyung Wu, Hanxin Liu Clinical/Regulatory/PM Louis Fries, D. Nigel Thomas, Eloi Kpamegan, Judy Wen, Dewal Jani, Somia Hickman, Matt Lawlor, Amy Fix, Kathleen Callahan, and Gregory Glenn. Baylor College of Medicine Pedro Pied